Brokerages Anticipate RedHill Biopharma Ltd (RDHL) Will Post Earnings of -$0.47 Per Share

Analysts expect that RedHill Biopharma Ltd (NASDAQ:RDHL) will report ($0.47) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have made estimates for RedHill Biopharma’s earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.45). RedHill Biopharma reported earnings of ($0.60) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 21.7%. The firm is expected to announce its next quarterly earnings results on Tuesday, July 24th.

According to Zacks, analysts expect that RedHill Biopharma will report full year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.70). For the next financial year, analysts forecast that the business will report earnings of ($1.30) per share, with EPS estimates ranging from ($1.70) to ($1.00). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover RedHill Biopharma.

RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). The firm had revenue of $2.45 million for the quarter, compared to analyst estimates of $2.14 million. RedHill Biopharma had a negative return on equity of 114.27% and a negative net margin of 726.64%.

Several research analysts recently weighed in on RDHL shares. ValuEngine raised RedHill Biopharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. HC Wainwright set a $36.00 price target on RedHill Biopharma and gave the company a “buy” rating in a research report on Wednesday, May 9th. Finally, Zacks Investment Research raised RedHill Biopharma from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research report on Saturday, May 12th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.95.

Large investors have recently bought and sold shares of the stock. Sabby Management LLC acquired a new position in RedHill Biopharma during the fourth quarter valued at $110,000. ARK Investment Management LLC acquired a new position in RedHill Biopharma during the fourth quarter valued at $149,000. Citadel Advisors LLC acquired a new position in RedHill Biopharma during the fourth quarter valued at $170,000. Meitav Dash Investments Ltd. acquired a new position in RedHill Biopharma in the 4th quarter worth about $244,000. Finally, Virtu Financial LLC acquired a new position in RedHill Biopharma in the 4th quarter worth about $312,000. 20.03% of the stock is currently owned by hedge funds and other institutional investors.

RedHill Biopharma traded down $0.19, hitting $7.00, during trading hours on Thursday, MarketBeat Ratings reports. 53,804 shares of the company’s stock traded hands, compared to its average volume of 96,426. The firm has a market capitalization of $152.53 million, a price-to-earnings ratio of -2.69 and a beta of 0.80. RedHill Biopharma has a twelve month low of $4.30 and a twelve month high of $11.25.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions.

Get a free copy of the Zacks research report on RedHill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply